dexrazoxane has been researched along with Genetic Predisposition in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andelfinger, G; Ansari, M; Bertout, L; Drouin, S; Elbared, J; Krajinovic, M; Kutok, JL; Laverdière, C; Lipshultz, SE; Neuberg, DS; Raboisson, MJ; Rezgui, A; Sallan, SE; Silverman, LB; Sinnett, D | 1 |
1 trial(s) available for dexrazoxane and Genetic Predisposition
| Article | Year |
|---|---|
Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Child; Child, Preschool; Dexrazoxane; Doxorubicin; Female; Genetic Predisposition to Disease; Heart Diseases; Heterozygote; Homozygote; Humans; Infant; Male; Multidrug Resistance-Associated Proteins; Myocardial Contraction; Nitric Oxide Synthase Type III; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protective Factors; Risk Assessment; Risk Factors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left; Young Adult | 2016 |